ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
LAUSANNE, Switzerland, April 01, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (the "Company") (NYSE: ADCT) today announced that the Company has made grants of options to purchase an aggregate of 53,800 of the Company's common shares to six new employees on April 1, 2024 (each, a "Grant"). The Grants were offered as material inducement to the employees' employment. The grants were approved by the Compensation Committee of the Company's Board of Directors pursuant to the Company's Inducement Plan to motivate and reward the recipients to perform at the highest levels and contribute significantly to the success of the Company. The Grants were made in reliance on the employment inducement exemption under the NYSE's Listed Company Manual Rule 303A.08. The Company is issuing this press release pursuant to Rule 303A.08. The Grants shall vest and become exercisable 25% on the first anniversary of the grant date, and 1/48th of the aggregate number of shares subject to the award on each monthly anniversary of the grant date thereafter, such that the entire award will be vested as of the fourth anniversary of the grant date, subject to continued employment with the Company.
瑞士洛桑，2024年4月1日（環球新聞專線）——ADC Therapeutics SA（“公司”）（紐約證券交易所代碼：ADCT）今天宣佈，公司已於2024年4月1日向六名新員工授予了購買公司總共53,800股普通股的期權（每股均爲 “補助金”）。這些補助金是作爲對僱員就業的物質刺激而提供的。根據公司的激勵計劃，這些補助金由公司董事會薪酬委員會批准，旨在激勵和獎勵接受者保持最高水平，爲公司的成功做出重大貢獻。補助金是根據紐約證券交易所上市公司手冊第303A.08條規定的就業激勵豁免發放的。該公司根據第303A.08條發佈本新聞稿。補助金應在撥款日一週年之日歸屬並可行使 25%，1/48第四 此後在授予之日的每個月週年紀念日受獎勵的股票總數，因此，全部獎勵將自授予之日起的四週年歸屬，前提是繼續在公司工作。
About ADC Therapeutics
關於ADC療法
ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.
ADC Therapeutics（紐約證券交易所代碼：ADCT）是抗體藥物偶聯物（ADC）領域的商業階段全球領導者和先驅者。該公司正在推進其專有的ADC技術，以改變血液系統惡性腫瘤和實體瘤患者的治療模式。
ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.
ADC Therapeutics的CD19靶向的ADC ZYNLONTA（loncastuximab tesirine-lpyl）獲得了美國食品藥品管理局的加速批准和歐盟委員會的有條件批准，用於治療兩條或更多線路全身治療後的復發或難治性瀰漫性大B細胞淋巴瘤。ZYNLONTA還正在與其他藥物聯合開發中，並已進入早期治療領域。除了 ZYNLONTA 之外，ADC Therapeutics 還有多個 ADC 正在進行臨床和臨床前開發。
ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information, please visit and follow the Company on LinkedIn.
ADC Therapeutics總部位於瑞士洛桑（Biopole），在倫敦、舊金山灣區和新澤西州開展業務。如需了解更多信息，請訪問並在 LinkedIn 上關注公司。
ZYNLONTA is a registered trademark of ADC Therapeutics SA.
ZYNLONTA 是 ADC Therapeutics SA 的註冊商標。
CONTACT:
Investors and Media
Nicole Riley
ADC Therapeutics
Nicole.Riley@adctherapeutics.com
+1 862-926-9040
聯繫人：
投資者和媒體
妮可·萊利
ADC 療法
Nicole.Riley@adctherapeutics.com
+1 862-926-9040